Current status and inspiration on macrolides in the treatment of chronic obstructive pulmonary disease

Open access

1. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23: 590-15.

2. Mikura S, Wada H, Higaki M, Yasutake T, Ishii H, Kamiya S, et al. Erythromycin prevents the pulmonary inflammation induced by exposure to cigarette smoke. Transl Res 2011; 158: 30-7.

3. Zhou Y, Tan X, Kuang W, Liu L, Wan L. Erythromycin ameliorates cigarette smoke-induced emphysema and inflammation in rats. Transl Res 2012 ; 159: 464-72.

4. Bai J, Qiu SL, Zhong XN, Huang QP, He ZY, Zhang JQ, et al. Erythromycin enhances CD4+Foxp3+ regulatory T-cell responses in a rat model of smoke-induced lung inflammation. Mediators Inflamm 2012; 2012: 410232.

5. He Z, Li B, Yu L, Liu Q, Zhong N, Ran P. Suppression of oxidantinduced glutathione synthesis by erythromycin in human bronchial epithelial cells. Respiration 2008; 75: 202-9.

6. Zhong XN, Guo SM. An experimental study on pulmonary vascular inflammation in a rat model of chronic bronchitis and emphysema. Chin J Tuberc Respir Dis 2006; 29: 435-9.

7. Duan MC, Tang HJ, Zhong XN, Huang Y. Persistence of Th17/Tc17 cell expression upon smoking cessation in mice with cigarette smokeinduced emphysema. Clin Dev Immunol 2013; 2013: 350727.

8. Yin C, Wang LM, Meng XY. Clinical observation of low dose theophylline combined with inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease. Med J Chin PLA 2007; 32: 777.

9. Li M, Zhong X, He Z, Wen M, Li J, Peng X, et al. Effect of erythromycin on cigarette-induced histone deacetylase protein expression and nuclear factor-kappaB activity in human macrophages in vitro. Int Immunopharmacol 2012; 12: 643-50.

10. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-47.

11. He ZY, Ou LM, Zhang JQ, Bai J, Liu GN, Li MH, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 2010; 80: 445-52.

12. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-98.

13. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van’t Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease(COLUMBUS): a randomised, doubleblind, placebo-controlled trial. Lancet Respir Med 2014; 2: 361-8.

14. Yao GY, Ma YL, Zhang MQ, Gao ZC. Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysis. Respiration 2013; 86: 254-60.

15. Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 2014; 189: 1503-8.

16. Simpson JL, Powell H, Baines KJ, Milne D, Coxson HO, Hansbro P. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS One 2014; 9: e105609.

17. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309: 1251-9.

18. Serisier DJ, Martin ML, McGuckin MA, Lourie R,Chen AC,Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; 309: 1260-7.

19. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366: 1881-90.

20. Svanström HH, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368: 1704-12.

21. Mortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014; 311: 2199-208.

22. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013; 1: 262-74.

23. Li YJ, Shimizu T, Hirata Y, Inagaki H, Takizawa H, Azuma A, et al. EM, EM703 inhibit NF-kB activation-induced by oxidative stress from diesel exhaust particle in human bronchial epithelial cells: importance in IL-8 transcription. Pulm Pharmacol Ther 2013; 26:318-24.

24. Mencarelli A, Distrutti E, Renga B, Cipriani S, Palladino G, Booth C, et al. Development of nonantibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis. Eur J Pharmacol 2011; 665:29-39.

25. Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C, Barnes PJ, et al. A novel macrolide/ fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol 2013; 169: 1024-34.

26. Kobayashi Y, Wada H, Rossios C, Takagi D, Higaki M, Mikura S, et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kappaB inhibition. J Pharmacol Exp Ther 2013;345:76-84.